Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07005102 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 854 | AbbVieINDUSTRY | 13 | Jun 8, 2026 | clinicaltrials |
| NCT07633626 | Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib | recruiting | — | 24 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo |
| 1 |
| Jun 8, 2026 |
| clinicaltrials |
| NCT07630246 | CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS(PAIR-LUNG) | not yet recruiting | — | 140 | Universidade Nova de LisboaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06463665 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer(VIRO-25) | recruiting | Phase 2 | 142 | Genelux CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05764954 | A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | active not recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06843629 | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors | recruiting | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06868836 | Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy | recruiting | Phase 2 | 78 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07485166 | Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases | active not recruiting | — | 810 | Brigham and Women's HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma(HARMONIC) | recruiting | Phase 2 | 90 | Lantern Pharma Inc.INDUSTRY | 3 | May 4, 2026 | clinicaltrials |
| NCT05191485 | Shared Decision Making in Patients With Lung Cancer | recruiting | — | 190 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05528458 | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma | recruiting | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04937283 | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | N/A | 690 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06181812 | Pathogenic Variants in Genes Associated With Lung Adenocarcinoma | recruiting | — | 332 | Oscar Gerardo Arrieta RodríguezOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | recruiting | Phase 2 | 50 | Emory UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05665504 | Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | recruiting | — | 250 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | terminated | Phase 1 | 24 | Imugene LimitedINDUSTRY | 2 | Mar 25, 2026 | clinicaltrials |
| NCT07479095 | Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma(KETO-FDG Lung) | recruiting | N/A | 30 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07012759 | Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients | recruiting | — | 100 | Fu Jen Catholic UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07264816 | A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC | recruiting | Phase 2 | 80 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05184712 | Phase 3 Clinical Study of AK112 for NSCLC Patients | active not recruiting | Phase 3 | 322 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07219251 | Engagement of Veterans With Lung Cancer(EVLC) | recruiting | N/A | 194 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT01345851 | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | active not recruiting | N/A | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | withdrawn | Phase 1 / Phase 2 | 0 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423169 | Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer | recruiting | N/A | 10 | Karl Landsteiner University of Health SciencesOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07416058 | PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC(PHOENIX) | not yet recruiting | Phase 2 | 61 | Guangdong Association of Clinical TrialsOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07392073 | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC | not yet recruiting | — | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07229339 | Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 500 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma(CRYOMUNE) | recruiting | Phase 3 | 214 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07373171 | Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching Hospital | not yet recruiting | N/A | 60 | Tribhuvan University, NepalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT07287904 | Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data | not yet recruiting | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer(Microlyvaq™) | enrolling by invitation | Early Phase 1 | 90 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07273279 | ADH1B and ALDH Gene Variants and Lung Cancer Risk(ALDH) | not yet recruiting | — | 100,000 | Kaohsiung Medical UniversityOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07178795 | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | recruiting | Phase 3 | 440 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03468426 | A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours | completed | Phase 1 | 252 | Boehringer IngelheimINDUSTRY | 12 | Nov 10, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | terminated | Phase 3 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2026source: clinicaltrials